科伦博泰生物-BExpect more important data release

招银国际
Aug 21, 2025

一、公司业绩及产品进展Kelun-Biotech(6990HK)在2025年上半年实现营收9.5亿元人民币,净亏损1.45亿元。其核心产品SKB264(sac-TMT)在晚期TNBC和EGFRm NSCLC适应症上已获批准,并贡献了3.02亿元销售额,占此前全年预测的34%。管理层预计SKB264在2025年的销售额将达到8亿至10亿元。二、重要临床数据发布预期公司计划在2025年ESMO会议上...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10